BCL2 and acute myeloid leukemia: Venetoclax is the only FDA-approved small-molecule inhibitor against BCL2 in acute myeloid leukemia (AML), and chronic lymphatic leukemia—yet other drugs might follow both in hematologic [67] and solid tumor malignancies [68].